Logo image of KMTS

KESTRA MEDICAL TECHNOLOGIES (KMTS) Stock Fundamental Analysis

USA - NASDAQ:KMTS - BMG524411052 - Common Stock

26.22 USD
+0.12 (+0.46%)
Last: 11/7/2025, 8:00:02 PM
26.22 USD
0 (0%)
After Hours: 11/7/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, KMTS scores 3 out of 10 in our fundamental rating. KMTS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. KMTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KMTS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KMTS had negative earnings in the past year.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

KMTS's Return On Assets of -48.70% is on the low side compared to the rest of the industry. KMTS is outperformed by 65.61% of its industry peers.
The Return On Equity of KMTS (-70.43%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.7%
ROE -70.43%
ROIC N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

KMTS's Gross Margin of 43.46% is on the low side compared to the rest of the industry. KMTS is outperformed by 62.96% of its industry peers.
KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KMTS remains at a similar level compared to 1 year ago.
The debt/assets ratio for KMTS has been reduced compared to a year ago.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 2025 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

KMTS has an Altman-Z score of 6.59. This indicates that KMTS is financially healthy and has little risk of bankruptcy at the moment.
KMTS has a better Altman-Z score (6.59) than 85.71% of its industry peers.
KMTS has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, KMTS is in line with its industry, outperforming 56.61% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 6.59
ROIC/WACCN/A
WACC8.76%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.84 indicates that KMTS has no problem at all paying its short term obligations.
KMTS's Current ratio of 6.84 is amongst the best of the industry. KMTS outperforms 84.66% of its industry peers.
KMTS has a Quick Ratio of 6.84. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.84, KMTS belongs to the best of the industry, outperforming 88.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.84
Quick Ratio 6.84
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for KMTS have decreased strongly by -25.08% in the last year.
The Revenue has grown by 115.05% in the past year. This is a very strong growth!
EPS 1Y (TTM)-25.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.99%
Revenue 1Y (TTM)115.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.55%

3.2 Future

The Earnings Per Share is expected to grow by 9.68% on average over the next years. This is quite good.
Based on estimates for the next years, KMTS will show a very strong growth in Revenue. The Revenue will grow by 48.26% on average per year.
EPS Next Y-13.42%
EPS Next 2Y0.04%
EPS Next 3Y9.68%
EPS Next 5YN/A
Revenue Next Year51.29%
Revenue Next 2Y49.54%
Revenue Next 3Y48.26%
Revenue Next 5YN/A

3.3 Evolution

KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 50M 100M 150M
KMTS Yearly EPS VS EstimatesKMTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KMTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KMTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.04%
EPS Next 3Y9.68%

More info and screens

0

5. Dividend

5.1 Amount

KMTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (11/7/2025, 8:00:02 PM)

After market: 26.22 0 (0%)

26.22

+0.12 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-11 2025-09-11/amc
Earnings (Next)N/A N/A
Inst Owners41.63%
Inst Owner ChangeN/A
Ins Owners1.36%
Ins Owner Change27.73%
Market Cap1.35B
Revenue(TTM)66.40M
Net Income(TTM)-129.69M
Analysts85
Price Target27.71 (5.68%)
Short Float %9.26%
Short Ratio7.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-135.31%
Min EPS beat(2)-312.7%
Max EPS beat(2)42.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.76%
Min Revenue beat(2)6.25%
Max Revenue beat(2)7.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.24%
PT rev (3m)1.24%
EPS NQ rev (1m)-7.19%
EPS NQ rev (3m)20.58%
EPS NY rev (1m)3.57%
EPS NY rev (3m)-19.12%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.32
P/FCF N/A
P/OCF N/A
P/B 7.33
P/tB 7.33
EV/EBITDA N/A
EPS(TTM)-2.6
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.29
BVpS3.58
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.7%
ROE -70.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.46%
FCFM N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.84
Quick Ratio 6.84
Altman-Z 6.59
F-ScoreN/A
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)226.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)88.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.99%
EPS Next Y-13.42%
EPS Next 2Y0.04%
EPS Next 3Y9.68%
EPS Next 5YN/A
Revenue 1Y (TTM)115.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.55%
Revenue Next Year51.29%
Revenue Next 2Y49.54%
Revenue Next 3Y48.26%
Revenue Next 5YN/A
EBIT growth 1Y-25.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.08%
EBIT Next 3Y21.66%
EBIT Next 5YN/A
FCF growth 1Y-19.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.44%
OCF growth 3YN/A
OCF growth 5YN/A

KESTRA MEDICAL TECHNOLOGIES / KMTS FAQ

What is the ChartMill fundamental rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KMTS.


What is the valuation status for KMTS stock?

ChartMill assigns a valuation rating of 0 / 10 to KESTRA MEDICAL TECHNOLOGIES (KMTS). This can be considered as Overvalued.


What is the profitability of KMTS stock?

KESTRA MEDICAL TECHNOLOGIES (KMTS) has a profitability rating of 0 / 10.


Can you provide the financial health for KMTS stock?

The financial health rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) is 6 / 10.


What is the earnings growth outlook for KESTRA MEDICAL TECHNOLOGIES?

The Earnings per Share (EPS) of KESTRA MEDICAL TECHNOLOGIES (KMTS) is expected to decline by -13.42% in the next year.